Stock info Assembly Biosciences | Filter  Basic-Info

Assembly Biosciences

Assembly Biosciences has located her head office Wisconsin. Assembly Biosciences's core business is the biotech sector. Philip B. Flynn is the company' CEO. Assembly Biosciences' CFO is Christopher J. Del MoralNiles. The global biotech companies gained around 59 percent over the period 2006-2016. Measured since 2011 the sector is 70 percent higher and over the past 12 months (December 2015-December 2016) there is a minus of 59 percent.

The past year was a good year for Assembly Biosciences investors

Over the last 12 months (from December 2015 till December 2016), that were profitable period for the investors in Assembly Biosciences, the stock gained around 65 percent. Over the past 5 years Assembly Biosciences' stock lost at around 66 percent in value. Assembly Biosciences's net results between 2011 and 2015 were relatively steady and moved between -34,34 million dollars and -28,45 million dollars.

The American company didn't pay out any dividends (in the past 5 years).

Assembly Biosciences financed with lots of debt

As per the end of 2015 the American company's balance sheet equaled 133,74 million dollars. At the end of 2015 the total debt positon equaled 15 million dollars. This is around 11,22 percent of the total balance sheet. Last year the biotech company's price/earnings-ratio (PE) was around -4. So the investors valued the stock at -4 times 2015' earnings per share. Based on it's price/earnings-ratio and dividend yield the American stock can be seen as a value stock.

At the end of 2015 the American company's market capitalization equaled around 108,35 million dollars. At the end of 2015 the American company had around 15,7 million stocks listed on the exchanges.

All the annual reports of Assembly Biosciences are available here. More information about Assembly Biosciences can be found it's website. .